Ralliant (NYSE:RAL) Reaches New 52-Week High – Still a Buy?

Ralliant Corporation (NYSE:RAL) reached a new 52-week high on Wednesday . The company traded as high as $70.99 and last traded at $71.4910, with a volume of 58575 shares. The stock had previously closed at $69.22.

Analysts Set New Price Targets

Several analysts have commented on the company. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Oppenheimer upped their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Morgan Stanley increased their target price on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, TD Cowen boosted their price target on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Stock Up 4.4%

The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The business has a 50 day simple moving average of $56.55 and a 200-day simple moving average of $50.80. The firm has a market capitalization of $8.09 billion and a price-to-earnings ratio of -6.60.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million for the quarter. Ralliant’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts expect that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Institutional Trading of Ralliant

Several hedge funds have recently made changes to their positions in the company. Viking Global Investors LP purchased a new stake in shares of Ralliant during the 2nd quarter valued at approximately $257,200,000. State Street Corp acquired a new position in Ralliant in the second quarter valued at approximately $213,096,000. Millennium Management LLC grew its position in Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares during the period. Norges Bank purchased a new position in Ralliant in the fourth quarter worth approximately $124,687,000. Finally, Invesco Ltd. increased its stake in Ralliant by 90.1% during the third quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after acquiring an additional 1,835,128 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.